A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma

Neuro-Oncology

Volumn 16, Issue 7, 2014, Pages 984-990

  Clarke, Jennifer L ^a   Molinaro, Annette M ^a   Phillips, Joanna J ^a   Butowski, Nicholas A ^a   Chang, Susan M ^a   Perry, Arie ^a   Costello, Joseph F ^a   Desilva, Ashley A ^a   Rabbitt, Jane E ^a   Prados, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bevacizumab; erlotinib; glioblastoma; radiation; temozolomide

Indexed keywords

BEVACIZUMAB; ERLOTINIB; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BODY WEIGHT DISORDER; BRONCHUS FISTULA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; ESOPHAGITIS; FEBRILE NEUTROPENIA; GLIOBLASTOMA; HEART INFARCTION; HERPES ESOPHAGITIS; HERPES SIMPLEX; HUMAN; HYPERTENSION; INVASIVE ASPERGILLOSIS; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; OPEN STUDY; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; SINGLE BLIND PROCEDURE; SUBARACHNOID HEMORRHAGE; THROMBOCYTOPENIA; TIME TO TREATMENT; TUMOR GROWTH; VENOUS THROMBOEMBOLISM; WOUND COMPLICATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; MALE; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; YOUNG ADULT;

EID: 84902457349     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou029     Document Type: Article

References (16)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
2. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068. Erratum in Nature. 2013;494:506.
3. Kaur B, Tan C, Brat DJ, et al. Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol. 2004;70(2):229-243.
4. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27(4):579-584.
5. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011; 29(2):142-148.
6. Hainsworth JD, Shih KC, Shepard GC, et al. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol. 2012;10(4): 240-246.
7. Henriksson R, Bottomley A, Mason W, et al. Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM) [abstract]. J Clin Oncol. 2013; 31(suppl, abstr 2005).
8. Gilbert MR, Dignam J, Won M, et al. RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM) [abstract]. J Clin Oncol. 2013;31(suppl, abstr 1).
9. Prasad G, Sottero T, Yang X, et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011;13(13):384-392.
10. Christensen BC, Smith AA, Zheng S, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst. 2011;103(2):143-153.
11. Elkhaled A, Jalbert LE, Phillips JJ, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med. 2012;4(116):116ra5.
12. Butowski N, Chang SM, Lamborn KR, et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011;13(12):1331-1338.
13. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353(19):2012-2024.
14. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16(8): 2443-2449.
15. Wefel J, Pugh S, Armstrong T, et al. Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825 [abstract]. J Clin Oncol. 2013;31(suppl, abstr 2004).
16. Armstrong T, Wefel J, Won M, et al. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825 [abstract]. J Clin Oncol. 2013;31(suppl, abstr 2003).